Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2017 to Q4 2025

Type / Class: Equity / Ordinary Shares, nominal value 0.05 GBP per share
Symbol: VRNA
Shares outstanding: 84,213,667
Price per share: $17.95
All holders as of 31 Dec 2025: Q4 2025
Total 13F shares: 20,000
Total reported value: $359,000
Share change: -37,667,122
Value change: -$4,019,144,582
Number of holders: 1
Price from insider filings: $17.95

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
Growth Equity Opportunities Fund IV, LLC	5%		$2,139,209,824		32,679,649		Scott D. Sandell	16 Jan 2025
MAVERICK CAPITAL LTD	3.8%		$1,638,341,259		25,028,128		Maverick Capital, Ltd.	31 Dec 2024
JANUS HENDERSON GROUP PLC	1.2%	-86%	$107,837,284	-$546,765,073	1,010,564	-84%	JANUS HENDERSON GROUP PLC	30 Sep 2025
RA CAPITAL MANAGEMENT, L.P.	0.7%	-91%	$62,198,806	-$567,585,398	593,670	-90%	RA Capital Management, L.P.	30 Jun 2025

As of 31 Dec 2025, 1 institutional investors reported holding 20,000 shares of Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA). This represents 0.02% of the company’s total 84,213,667 outstanding shares.

Institutional Holders of Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q4	20,000	$359,000	-$4,019,144,582	$0	$0	$17.95	1
2025 Q3	80,398,842	$8,578,750,126	+$837,023,417	$47,796,069	$68,143,366	$106.71	243
2025 Q2	75,959,176	$7,178,711,698	+$377,068,942	$294,836,202	$84,784,815	$94.58	291
2025 Q1	72,226,156	$4,575,336,285	+$289,861,737	$125,547,483	$53,802,540	$63.49	258
2024 Q4	68,611,559	$3,186,422,108	+$45,832,094	$13,865,004	$58,806,848	$46.44	192
2024 Q3	67,675,281	$1,950,276,918	+$158,137,487	$19,669,972	$17,376,871	$28.77	149
2024 Q2	66,174,147	$956,862,178	-$15,389,539	$7,005,870	$5,484,678	$14.46	125
2024 Q1	66,961,392	$1,084,932,320	-$17,301,242	$1,075,812	$1,028,151	$16.09	113
2023 Q4	67,202,638	$1,345,422,422	+$16,673,493	$3,009,832	$1,439,312	$19.88	116
2023 Q3	64,968,404	$1,066,709,124	+$34,858,183	$2,453,150	$800,330	$16.30	101
2023 Q2	62,584,885	$1,332,969,384	+$50,184,333	$1,653,148	$2,390,934	$21.14	104
2023 Q1	60,335,461	$1,211,517,782	+$167,801,714	$1,993,944	$1,608,408	$20.08	93
2022 Q4	50,105,712	$1,309,183,295	+$112,055,574	$4,826,211	$22,654,710	$26.13	88
2022 Q3	51,774,348	$528,758,643	+$182,949,663	$1,847,000	$5,362,500	$10.22	65
2022 Q2	34,799,135	$145,683,724	-$8,606,491		$388,000	$4.19	36
2022 Q1	36,443,868	$181,735,244	-$2,536,945	$0	$74,000	$4.99	38
2021 Q4	36,936,117	$248,013,599	+$379,094	$264,000		$6.72	41
2021 Q3	37,018,796	$202,742,194	+$753,340			$5.48	38
2021 Q2	36,699,886	$239,939,874	+$947,435	$0		$6.54	35
2021 Q1	36,531,198	$305,130,909	+$6,927,568	$99,000	$0	$8.36	36
2020 Q4	35,736,138	$246,007,905	+$8,102,449	$104,000	$85,000	$7.00	34
2020 Q3	34,077,017	$212,640,000	+$168,041,172			$6.24	28
2020 Q2	7,173,525	$33,588,000	+$911,545			$4.68	18
2020 Q1	6,984,029	$28,790,000	+$4,644,284			$4.12	14
2019 Q4	5,849,679	$33,680,000	+$46,378			$5.75	13
2019 Q3	5,862,079	$26,791,000	-$7,634,329			$4.57	12
2019 Q2	7,368,227	$37,584,000	-$77,763			$5.10	16
2019 Q1	7,381,315	$47,545,000	-$1,633,811			$6.50	17
2018 Q4	8,407,168	$78,583,000	-$2,815,272			$9.05	17
2018 Q3	7,376,882	$92,275,000	+$11,046,083			$12.51	14
2018 Q2	6,490,956	$71,091,000	-$1,254,345			$13.66	13
2018 Q1	6,582,135	$131,642,000	-$1,915,281			$20.00	14
2017 Q4	6,677,932	$79,300,000	+$6,207,670			$11.87	10
2017 Q3	5,279,998	$81,047,000	+$20,684,812			$15.35	9
2017 Q2	3,954,155	$46,085,000	+$46,085,000			$11.66	9